How many insider trades does FilingIQ track for XLO?

FilingIQ tracks 129 Form 4 insider transactions for XLO (Xilio Therapeutics, Inc.), covering filings from Oct 26, 2021 onwards. 2 of those were filed in the last 90 days.

Are XLO insiders net buyers or net sellers?

Across the full Form 4 history for XLO, 19 transactions (15%) were open-market purchases and 10 (8%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does XLO insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is XLO in?

Xilio Therapeutics, Inc. (XLO) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $39.77M.

XLO insider trading

NasdaqCM Healthcare

Xilio Therapeutics, Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

129

Last 90 days

Buys / sells

15% / 8%

Market cap

$39.77M

About Xilio Therapeutics, Inc.

Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company's checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors. It also develops cytokine programs, which comprises XTX202, a tumor-activated beta-gamma biased IL-2, currently under Phase 2 clinal trials; and XTX301, an investigational tumor-activated, engineered IL-12 molecule, currently under Phase 1 studies. The company was founded in 2016 and is headquartered in Waltham, Massachusetts.

Company website: xiliotx.com

XLO insider activity at a glance

FilingIQ has scored 129 insider transactions for XLO since Oct 26, 2021. The most recent filing in our index is dated Apr 15, 2026.

Across the full history, 19 open-market purchases and 10 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on XLO insider trades is 47.1/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live XLO trades on FilingIQ Raw filings on SEC EDGAR

Other Healthcare tickers with recent insider activity

UTHR 1,098

UNITED THERAPEUTICS Corp

APLS 279

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

BMY 185

BRISTOL MYERS SQUIBB CO

ADPT 184

Adaptive Biotechnologies Corp

GH 169

Guardant Health, Inc.

ISRG 166

INTUITIVE SURGICAL INC

VTRS 165

Viatris Inc

Frequently asked

How many insider trades does FilingIQ track for XLO?: FilingIQ tracks 129 Form 4 insider transactions for XLO (Xilio Therapeutics, Inc.), covering filings from Oct 26, 2021 onwards. 2 of those were filed in the last 90 days.
Are XLO insiders net buyers or net sellers?: Across the full Form 4 history for XLO, 19 transactions (15%) were open-market purchases and 10 (8%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does XLO insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is XLO in?: Xilio Therapeutics, Inc. (XLO) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $39.77M.

Methodology & sources

Every XLO insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.